PT3353167T - Moduladores da indolamina 2,3-dioxigenase - Google Patents
Moduladores da indolamina 2,3-dioxigenaseInfo
- Publication number
- PT3353167T PT3353167T PT167749928T PT16774992T PT3353167T PT 3353167 T PT3353167 T PT 3353167T PT 167749928 T PT167749928 T PT 167749928T PT 16774992 T PT16774992 T PT 16774992T PT 3353167 T PT3353167 T PT 3353167T
- Authority
- PT
- Portugal
- Prior art keywords
- indoleamine
- dioxygenase
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/76—Sulfur atoms attached to a second hetero atom
- C07D277/80—Sulfur atoms attached to a second hetero atom to a nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562222880P | 2015-09-24 | 2015-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3353167T true PT3353167T (pt) | 2020-09-17 |
Family
ID=57045239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT167749928T PT3353167T (pt) | 2015-09-24 | 2016-09-22 | Moduladores da indolamina 2,3-dioxigenase |
Country Status (12)
Country | Link |
---|---|
US (1) | US10358427B2 (pt) |
EP (1) | EP3353167B1 (pt) |
JP (1) | JP6775010B2 (pt) |
KR (1) | KR20180056729A (pt) |
CN (1) | CN108260355A (pt) |
AU (1) | AU2016327167B2 (pt) |
BR (1) | BR112018005904A2 (pt) |
CA (1) | CA2998826A1 (pt) |
ES (1) | ES2814251T3 (pt) |
PT (1) | PT3353167T (pt) |
RU (1) | RU2018112749A (pt) |
WO (1) | WO2017051353A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3558966A1 (en) * | 2016-12-20 | 2019-10-30 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
EP3558978A1 (en) | 2016-12-20 | 2019-10-30 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
WO2018136437A2 (en) | 2017-01-17 | 2018-07-26 | Tesaro, Inc. | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
RU2020105929A (ru) | 2017-08-04 | 2021-09-06 | Скайхоук Терапьютикс, Инк. | Способы и композиции для модулирования сплайсинга |
US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
EP3823604A4 (en) | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | COMPOUNDS USEFUL AS INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE INHIBITORS |
US20210299126A1 (en) * | 2018-07-23 | 2021-09-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11992489B2 (en) | 2018-08-17 | 2024-05-28 | Merck Sharp & Dohme Llc | Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
CN109053624B (zh) * | 2018-09-26 | 2022-11-22 | 河南师范大学 | 具有ido抑制活性的噻唑类衍生化合物、制备方法及其用途 |
JP2022521467A (ja) | 2019-02-05 | 2022-04-08 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
WO2021102618A1 (en) * | 2019-11-25 | 2021-06-03 | InventisBio Co., Ltd. | Novel salts of indoleamine 2,3-dioxygenase inhibitors |
KR20230152715A (ko) | 2021-03-05 | 2023-11-03 | 유니버시타트 바셀 | Ebv 관련 질환 또는 질병의 치료용 조성물 |
EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
KR20110137941A (ko) * | 2010-06-18 | 2011-12-26 | (주) 에빅스젠 | 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 |
US9505728B2 (en) * | 2012-03-09 | 2016-11-29 | Inception 2, Inc. | Triazolone compounds and uses thereof |
US9145412B2 (en) * | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
BR112015021999A8 (pt) * | 2013-03-15 | 2019-12-03 | Bristol Myers Squibb Co | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase |
EA029126B1 (ru) * | 2013-07-01 | 2018-02-28 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
EP3019488B1 (en) * | 2013-07-11 | 2018-11-07 | Bristol-Myers Squibb Company | Ido inhibitors |
MX2016002075A (es) * | 2013-08-27 | 2016-05-26 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (ido). |
-
2016
- 2016-09-22 AU AU2016327167A patent/AU2016327167B2/en not_active Ceased
- 2016-09-22 ES ES16774992T patent/ES2814251T3/es active Active
- 2016-09-22 KR KR1020187011163A patent/KR20180056729A/ko unknown
- 2016-09-22 CN CN201680068738.9A patent/CN108260355A/zh active Pending
- 2016-09-22 RU RU2018112749A patent/RU2018112749A/ru not_active Application Discontinuation
- 2016-09-22 BR BR112018005904-8A patent/BR112018005904A2/pt not_active Application Discontinuation
- 2016-09-22 US US15/759,950 patent/US10358427B2/en not_active Expired - Fee Related
- 2016-09-22 EP EP16774992.8A patent/EP3353167B1/en active Active
- 2016-09-22 CA CA2998826A patent/CA2998826A1/en not_active Abandoned
- 2016-09-22 PT PT167749928T patent/PT3353167T/pt unknown
- 2016-09-22 WO PCT/IB2016/055674 patent/WO2017051353A1/en active Application Filing
- 2016-09-22 JP JP2018515289A patent/JP6775010B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20180290988A1 (en) | 2018-10-11 |
AU2016327167A1 (en) | 2018-04-12 |
RU2018112749A (ru) | 2019-10-24 |
CA2998826A1 (en) | 2017-03-30 |
KR20180056729A (ko) | 2018-05-29 |
ES2814251T3 (es) | 2021-03-26 |
AU2016327167B2 (en) | 2018-11-08 |
EP3353167A1 (en) | 2018-08-01 |
JP2018532727A (ja) | 2018-11-08 |
CN108260355A (zh) | 2018-07-06 |
BR112018005904A2 (pt) | 2018-10-16 |
EP3353167B1 (en) | 2020-06-24 |
WO2017051353A1 (en) | 2017-03-30 |
JP6775010B2 (ja) | 2020-10-28 |
US10358427B2 (en) | 2019-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283582A (en) | ror - gamma modulators | |
PT3353167T (pt) | Moduladores da indolamina 2,3-dioxigenase | |
HK1247922A1 (zh) | 用於治療癌症的吲哚胺2,3-雙加氧酶抑制劑 | |
HK1256599A1 (zh) | ROR-γ的調節劑 | |
IL252550A0 (en) | Cannabinoid compounds through the skin | |
EP3389783A4 (en) | NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS | |
SG11201706729SA (en) | Derivatives of sobetirome | |
HK1213447A1 (zh) | 雙不對稱鞋子 | |
IL252311B (en) | 4-oxo-4,3-dihydro-3,2,1-benzotriazines as G protein-coupled receptor modulators 139 | |
EP3139943A4 (en) | Combinations of nmdar modulating compounds | |
HK1231649A1 (zh) | 調製配置的信令 | |
IL247149A0 (en) | New Cannabigrol History | |
PT3142641T (pt) | Formulações para o tratamento de hipertiroidismo | |
HK1232121A1 (zh) | 作為抗氧化治療的富勒烯化合物 | |
HK1257091A1 (zh) | 茚烷衍生物作為mglur7調節劑 | |
IL248027B (en) | A new use of n,n-bis-2-mercaptoethyl isophthalamide | |
PT3377106T (pt) | Modulação da ciliogénese | |
GB201607437D0 (en) | New use of pemirolast | |
GB201607438D0 (en) | New use of pemirolast | |
PT3165222T (pt) | Utilização do composto de ftalida |